Are we getting an opportunity now to buy ResMed?
The share price of ResMed (RMD) has shed almost 10 per cent since the start of August. It’s now trading on a P/E of ~20x, compared to ~24x around the time of their fiscal year result. There are however some concerns in the market about an expected impact on gross margins from pricing pressure from its US customers. Looking at the chart, we are can also identify some key levels that RMD needs to respect. (VIEW LINK)
1 stock mentioned
most popular
Asset Allocation
Macquarie reveals its 16-stock "recession-proof" portfolio
Hans Lee,
Livewire Markets
Equities
Morgans’ 12 large-cap best ideas - June 2022
Andrew Tang,
Morgans Financial
Education
What ASX stocks would Warren Buffett buy in 2022?
Chris Leithner,
Leithner & Company Ltd